Analyst Price Targets — EXAS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 20, 2026 10:10 am | — | Mizuho Securities | $105.00 | $102.43 | TheFly | Exact Sciences downgraded to Neutral from Outperform at Mizuho |
| January 5, 2026 11:21 am | — | Evercore ISI | $105.00 | $101.74 | TheFly | Exact Sciences downgraded to In Line from Outperform at Evercore ISI |
| November 28, 2025 8:58 pm | — | Stifel Nicolaus | $105.00 | $101.29 | TheFly | Exact Sciences downgraded to Hold from Buy at Stifel |
| November 25, 2025 2:04 am | — | Canaccord Genuity | $105.00 | $101.01 | TheFly | Exact Sciences downgraded to Hold from Buy at Canaccord |
| November 24, 2025 2:50 pm | David Westenberg | Piper Sandler | $105.00 | $101.00 | TheFly | Exact Sciences downgraded to Neutral from Overweight at Piper Sandler |
| November 24, 2025 5:23 am | Tycho Peterson | Jefferies | $105.00 | $100.90 | StreetInsider | Jefferies Downgrades Exact Sciences (EXAS) to Hold |
| November 21, 2025 2:49 pm | Bill Bonello | Craig-Hallum | $105.00 | $100.67 | TheFly | Exact Sciences downgraded to Hold from Buy at Craig-Hallum |
| November 20, 2025 11:26 pm | — | Barclays | $105.00 | $100.67 | TheFly | Exact Sciences downgraded to Equal Weight from Overweight at Barclays |
| November 20, 2025 9:23 pm | — | Wells Fargo | $105.00 | $86.18 | TheFly | Exact Sciences downgraded to Equal Weight from Overweight at Wells Fargo |
| November 20, 2025 3:16 pm | Catherine Ramsey Schulte | Robert W. Baird | $105.00 | $101.34 | TheFly | Exact Sciences downgraded to Neutral from Outperform at Baird |
Latest News for EXAS
DNB Asset Management AS boosted its position in Exact Sciences Corporation (NASDAQ: EXAS) by 15.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 246,639 shares of the medical research company's stock after purchasing an additional 33,071 shares
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed acquisition of Exact Sciences by Abbott (NYSE: ABT) at the special meeting of stockholders held earlier today. At the special meeting, preliminary results showed that more than 99% of the votes…
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
EXAS posts Q4 revenue beat as Screening and Precision Oncology grow, margins expand, shares tick up and Abbott merger plans progress.
Aberdeen Group plc raised its holdings in shares of Exact Sciences Corporation (NASDAQ: EXAS) by 52.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 304,609 shares of the medical research company's stock after acquiring an additional 105,138 shares during the quarter.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for EXAS.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.